Unbound MEDLINE

Extra-osseous Ewing sarcoma. Pediatric hematology and oncology [Pediatr Hematol Oncol] Journal article

 
van den Berg H, Heinen RC, van der Pal HJ, Merks JH 
Extra-osseous Ewing sarcoma. [Journal Article]
Pediatr Hematol Oncol 2009 Jun; 26(4):175-85.


BACKGROUND: Clinical data and data on outcome of extra-osseous Ewing tumors are scarce.
PROCEDURE: After a search for Ewing tumors in the database of a single institution over a period of 20 years, 16 out of 192 cases were found to have extra-osseous primary tumors.
RESULTS: Ages at initial diagnosis ranged from 2.5 to 17 years. Follow-up period ranged from 4 months to 24.8 years (mean 8.4 years). Eleven patients were treated according to protocols for Ewing tumors, while in 4 cases soft tissue protocols were used. In a single patient only surgery was done. Two patients had progressive disease despite chemotherapy; a third patient had only tumor response on the initial 2 chemotherapy courses. All 3 patients with initially metastatic disease died. One patient developed a second malignancy. Overall survival at 5 years was 75%. Event-free survival (EFS) at 5 years was 68%; for nonmetastatic patients 5-year EFS was 83%.
CONCLUSION: The authors conclude that nonmetastasized extra-osseous Ewing tumors have a prognosis at least similar to that of osseous Ewing tumors.



More from this journal
  
Advertise on this site.